Archives
Y-27632 dihydrochloride: Selective ROCK Inhibitor for Cyt...
Y-27632 dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Stem Cell Research
Executive Summary: Y-27632 dihydrochloride is a cell-permeable, highly selective inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, demonstrating IC50 values of 140 nM and Ki of 300 nM, respectively (APExBIO, Product page). It exhibits over 200-fold selectivity over related kinases such as PKC and MLCK, making it a gold standard in Rho/ROCK signaling studies. The compound enhances stem cell viability and proliferation by inhibiting stress fiber formation and modulating cell cycle progression (Yu et al., DOI:10.1007/978-1-0716-3259-8_16). In vivo, Y-27632 reduces tumor invasion and metastasis in mouse models. Its physicochemical properties—high aqueous solubility and stability—facilitate diverse applications in cell biology and oncology research (APExBIO, A3008 kit).
Biological Rationale
Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases that regulate actin cytoskeleton dynamics, cell adhesion, migration, and cytokinesis. The Rho/ROCK signaling axis is central to cell shape, contractility, and motility. In embryonic development, pluripotency transitions, and cancer metastasis, ROCK activity orchestrates cytoskeletal remodeling and cell cycle progression (Yu et al. 2023). Selective inhibition of ROCK kinases allows precise modulation of stress fiber formation and cell–cell junction integrity. Y-27632 dihydrochloride, by targeting the catalytic domains of ROCK1/2, provides a tool to dissect the biological consequences of Rho/ROCK signaling in vitro and in vivo. Recent studies in pluripotent stem cells and cancer biology have relied on Y-27632 to delineate the roles of cytoskeletal tension and cell migration in tissue morphogenesis and disease progression.
Mechanism of Action of Y-27632 dihydrochloride
Y-27632 dihydrochloride is a small-molecule inhibitor that binds competitively to the ATP-binding pocket of ROCK1 and ROCK2. The compound inhibits ROCK1 with an IC50 of approximately 140 nM and ROCK2 with a Ki of 300 nM, demonstrating over 200-fold selectivity against kinases such as protein kinase C (PKC), cAMP-dependent protein kinase (PKA), myosin light-chain kinase (MLCK), and p21-activated kinase (PAK) (APExBIO). This selectivity profile minimizes off-target effects in cell-based assays. Upon ROCK inhibition, downstream phosphorylation of myosin light chain is reduced, leading to loss of actin stress fibers, alteration in focal adhesions, and impaired cell contractility. In stem cell cultures, Y-27632 prevents apoptosis associated with single-cell dissociation and enhances survival by stabilizing the actin cortex (Yu et al. 2023). In cancer models, repression of ROCK activity attenuates invasion and metastasis by reducing cytoskeletal-driven motility.
Evidence & Benchmarks
- Inhibition of ROCK1 activity by Y-27632 achieves an IC50 of 140 nM in enzymatic assays (APExBIO, Product data).
- Y-27632 demonstrates over 200-fold selectivity against PKC, PKA, MLCK, and PAK, minimizing off-target kinase inhibition (APExBIO).
- Application of 10 μM Y-27632 in stem cell cultures increases survival rates during passage by more than fivefold compared to controls (Yu et al. 2023).
- Y-27632 suppresses stress fiber formation in fibroblasts within 30 minutes of treatment at 37°C (APExBIO, A3008 kit).
- In mouse models, intraperitoneal administration of Y-27632 (10 mg/kg) reduces tumor invasion and metastasis, as measured by histopathology (Yu et al. 2023).
- Y-27632 is soluble at ≥52.9 mg/mL in water, facilitating preparation of concentrated stocks for in vitro assays (APExBIO, solubility data).
Applications, Limits & Misconceptions
Y-27632 dihydrochloride is widely used in cell biology, cancer research, and stem cell applications. It enables the study of Rho/ROCK pathway functions, cell motility, barrier integrity, and stem cell viability. The compound is a standard reagent in protocols for dissociation and maintenance of human and mouse pluripotent stem cells (Yu et al. 2023). In oncology, Y-27632 is used to model tumor cell invasion and test therapeutic strategies targeting actomyosin contractility.
For an extended discussion on 3D organoid modeling and cancer research, see Y-27632 Dihydrochloride: Next-Gen ROCK Inhibitor in 3D Organoids; this article updates the field with new data on in vivo tumor suppression and quantitative benchmarks in stem cell resilience.
To explore applications in neuro-epithelial barrier function, consult Advanced Applications in Neuro-Epithelial Modeling; the current review clarifies selectivity metrics and protocol parameters for broader cell types.
For practical workflow optimization, Reliable ROCK Inhibitor for Cell Viability and Cytoskeletal Studies offers experimental tips, while this article focuses on mechanistic specificity and evidence synthesis.
Common Pitfalls or Misconceptions
- Y-27632 is not effective in inhibiting kinases outside the ROCK family; it does not target PKC, PKA, MLCK, or PAK at standard assay concentrations.
- Long-term storage of aqueous Y-27632 solutions at ambient temperature reduces potency; aliquots should be stored at ≤-20°C for maximal stability.
- Y-27632 does not induce pluripotency or differentiation on its own; it supports cell survival during manipulations but is not a lineage-specifying factor.
- Antitumoral effects observed in mouse models are not directly translatable to clinical efficacy in humans without further validation.
- ROCK inhibition by Y-27632 may mask contractility-dependent phenotypes, potentially confounding migration or morphogenesis studies if not controlled.
Workflow Integration & Parameters
The recommended working concentration of Y-27632 dihydrochloride in cell culture is 10 μM, with solubility in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), and water (≥52.9 mg/mL) (APExBIO, solubility data). For optimal dissolution, pre-warm the solvent to 37°C or use an ultrasonic bath. Prepare fresh working solutions from concentrated stocks stored at -20°C; avoid repeated freeze-thaw cycles. For stem cell applications, Y-27632 is typically added during cell dissociation and the first 24–48 hours post-plating. In tumor invasion assays, dosing regimens in animal models range from 1–10 mg/kg/day intraperitoneally, depending on experimental endpoints (Yu et al. 2023). Desiccated solid is stable at 4°C or below. Researchers should validate the absence of cytotoxicity or off-target effects in new cell lines or assay formats.
Conclusion & Outlook
Y-27632 dihydrochloride (SKU A3008, APExBIO) is a validated, highly selective ROCK1/2 inhibitor with broad utility in cytoskeletal and stem cell research. Its quantitative selectivity, solubility, and stability parameters support reproducible results across diverse platforms. While its applications in cancer, developmental, and barrier function studies are well established, users should be aware of limitations related to specificity and context-dependent outcomes. Future research may expand the therapeutic and mechanistic insights by leveraging Y-27632 in combination with genetic or small-molecule perturbations. For product specifications and ordering, see the Y-27632 dihydrochloride product page.